Abstract
Biomarkers play an increasingly important role for drug efficacy and safety evaluation in all stages of drug development. It is especially important to develop and validate sensitive and selective biomarkers for diseases where the onset of the disease is very slow and/or the disease progression is hard to follow, i.e., osteoarthritis (OA). The degradation of Type II collagen has been associated with the disease state of OA. Matrix metalloproteinases (MMPs) are enzymes that catalyze the degradation of collagen and therefore pursued as potential targets for the treatment of OA. Peptide biomarkers of MMP activity related to type II collagen degradation were identified and the presence of these peptides in MMP digests of human articular cartilage (HAC) explants and human urine were confirmed. An immunoaffinity LC/MS/MS assay for the quantification of the most abundant urinary type II collagen neoepitope (uTIINE) peptide, a 45-mer with 5 HO-proline residues was developed and clinically validated. The assay has subsequently been applied to analyze human urine samples from clinical studies. We have shown that the assay is able to differentiate between symptomatic OA and normal subjects, indicating that uTIINE can be used as potential biomarker for OA. This chapter discusses the assay procedure and provides information on the validation experiments used to evaluate the accuracy, precision, and selectivity data with attention to the specific challenges related to the quantification of endogenous protein/peptide biomarker analytes. The generalized approach can be used as a follow-up to studies whereby proteomics-based urinary biomarkers are identified and an assay needs to be developed. Considerations for the validation of such an assay are described.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Huebner, J.L., Otterness, I.G., Freund, E.M., Caterson, B. and Kraus V.B. (1998) Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis, Arthritis Rheum 41, 877–890.
Kraus, V.B., Stabler, T.E., Le, T., Saltarelli, M. and Allen, N.B. (2003) Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis, Arthritis Rheum 48, 2942–2948.
Poole, A.R. (2003) Biochemical/immunochemical biomarkers of osteoarthritis: Utility for prediction of incident or progressive osteoarthritis, Rheum Dis Clin North Am 29(4), 803–818.
Nemirovskiy, O.V., Dufield, D.R., Sunyer, T., Aggarwal P., Welsch, D.J. and Mathews, W. R. (2007) Discovery and development of a type II collagen neoepitope (TIINE) biomarker for MMP activity: From in-vitro to in-vivo. Anal Biochem 391, 93–101.
Kindt, E., Shum, Y., Badura, L., Snyder, P.J., Brant, A., Fountain, S. and Szekely-Klepser, G. (2004) Development and validation of an LC/MS/MS procedure for the quantification of endogenous myo-inositol concentrations in rat brain tissue homogenates, Anal Chem 76(16), 4901–4908.
Li, W. and Cohen, L. (2003) Quantitation of endogenous analytes in biofluid without a true blank matrix, Anal Chem 75, 5854.
Jemal, M., Schuster, A. and Whigan, D.B. (2003) Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: Method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard, Rapid Commun Mass Spectrom 17(15), 1723–1734.
Szekely-Klepser, G., Wade, K., Woolson, D., Brown, R., Fountain, S. and Kindt, E. (2005) A validated LC/MS/MS method for the quantification of pyrrole-2,3,5-tricarboxylic acid (PTCA), a eumelanin specific biomarker, in human skin biopsies, J Chromatogr B 826, 31–40.
Conference on “Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies” held in December 1990 in Crystal City, VA, and sponsored by the FDA, AAPS, HPB of Canada, AOAC, and Federation International Pharmaceutique.
“AAPS Workshop on Bioanalytical Methods Validation- A Revisit with a decade of progress” held in January 2000 in Crystal City, VA cosponsored with the FDA. Guidance for Industry, Bioanalytical method validation”, issued by U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM) in May 2001.
Li, W., Nemirovskiy, O.V., Fountain, S., Mathews, W.R. and Szekely-Klepser, G. (2007) Clinical validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide: A biomarker of matrix metalloproteinase activity and osteoarthritis in human urine, Anal Biochem 369, 41–53.
Pickering E., Szekely-Klepser G., Nemirovskiy O., Li W., Brown R., Sunyer T. and Hellio Le Graverand M.-P. (2004) Urinary type II collagen neo-epitope (uTIINE): A marker of osteoarthritis activity, Osteoarthr Cartil 12(Suppl. B) S93.
Hellio Le Graverand, M-P., Brandt, K.D., Mazzuza, S.A., Katz, B.P., Buck, R., Lane, K.A., Pickering, E., Nemirovskiy, O.V., Sunyer, T. and Welsch, D.J. (2006) Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis, Osteoarthr Cartil 14(11), 1189–95.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Nemirovskiy, O., Li, W.W., Szekely-Klepser, G. (2010). Design and Validation of an Immunoaffinity LC–MS/MS Assay for the Quantification of a Collagen Type II Neoepitope Peptide in Human Urine: Application as a Biomarker of Osteoarthritis. In: Rai, A. (eds) The Urinary Proteome. Methods in Molecular Biology, vol 641. Humana Press. https://doi.org/10.1007/978-1-60761-711-2_15
Download citation
DOI: https://doi.org/10.1007/978-1-60761-711-2_15
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-710-5
Online ISBN: 978-1-60761-711-2
eBook Packages: Springer Protocols